Objective This study aims to evaluate the influence of myocardial scar after premature ventricular complexes (PVC) ablation in patients with left ventricular (LV) dysfunction.
Methods 70 consecutive patients (58±11 years, 58 (83%) men, 23% (18–32) mean PVC burden) with LV dysfunction and frequent PVCs submitted for ablation were included. A late gadolinium enhancement cardiac magnetic resonance (LGE-CMR) was performed prior to the ablation and a quantitative and qualitative analysis of the scar was done.
Results Left ventricular ejection fraction progressively improved from 34.3%±9% at baseline to 44.4%±12% at 12 months (p<0.01) and 48 (69%) patients were echocardiographic responders. New York Heart Association class improved from 1.96±0.9 points at baseline to 1.36±0.6 at 12 months (p<0.001). Brain natriuretic peptide decreased from 120 (60–284) to 46 (23–81) pg/mL (p=0.04). Twenty-nine (41%) patients showed scar in the preprocedural LGE-CMR with a mean scar mass of 10.4 (5–20) g. Mean scar mass was significantly smaller in responders than in non-responders (0 (0–4.7) g vs 2 (0–14) g, respectively, p=0.017). PVC burden reduction (OR 1.09 (1.01–1.16), p=0.02) and scar mass (OR 0.9 (0.81–0.99), p=0.04) were independent predictors of response, but the former showed a higher accuracy.
Conclusions Presence of myocardial scar modulates, but does not preclude, the probability of response to PVC ablation in patients with LV dysfunction.
- premature ventricular complex
- left ventricular dysfunction
- myocardial scar
- cardiac magnetic resonance
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
DP and MM contributed equally.
Contributors DP, MM and AB wrote the manuscript. DP, JF-A, LM and AB planned the study. RB performed the statistical analysis. LA, LT, AO, JA, JM-A, FB, LR, ML, DS-I, BJ, JTO-P, RJP and XB collected data. AB is responsible for the overall content as guarantor.
Funding This work was supported by Instituto de Salud Carlos III (Madrid, Spain) through the project “PI14/00759” (Co-funded by European Regional Development Fund/European Social Fund "Investing in your future").
Competing interests None declared.
Patient consent Obtained.
Ethics approval The present observational study complies with the Declaration of Helsinki and was approved by the local regulatory authorities.
Provenance and peer review Not commissioned; externally peer reviewed.